Key takeaways
- Levothyroxine remains first-line treatment for primary hypothyroidism in NICE guidance. Liothyronine is not routinely recommended alone or in combination. NICE thyroid guideline.
- T4 provides hormone that the body can convert to T3; adding T3 changes the pattern of hormone exposure, not simply the “strength” of treatment. American Thyroid Association explanation.
- Persistent symptoms deserve review even when TSH is in range. NICE advises considering FT4 testing as well in people still symptomatic on treatment. NICE monitoring recommendations.
- Research has not established consistent superiority of combined T4/T3 treatment, although carefully selected, supervised trials remain a clinical discussion. ATA summary of the joint consensus.
- Too much thyroid hormone can cause heart-rhythm problems and bone loss. Feeling more stimulated is not proof of better replacement. ATA treatment information.
Being told your thyroid result is normal while you still feel exhausted can leave you wondering what the test has missed. It is a reasonable question. The answer should be a review of treatment and symptoms, not an automatic dismissal or an automatic T3 prescription.
Eltroxin and Synthroid are levothyroxine brands, containing T4. Cytomel contains liothyronine, or T3. The difference is about how thyroid hormone is supplied and handled by the body, rather than an older medicine versus an inherently better one. South African Eltroxin leaflet, ATA explanation.
How do T4 and T3 differ?
T4 provides a relatively steady supply that the body can convert to T3; liothyronine produces a shorter-acting pattern.
The thyroid normally supplies both hormones, and other tissues convert T4 into T3. Levothyroxine uses that conversion process. Oral liothyronine supplies T3 directly, but its shorter action can produce peaks and troughs that complicate treatment. ATA explanation.
| Feature | Levothyroxine: T4 | Liothyronine: T3 |
|---|---|---|
| Examples of brand names | Eltroxin, Synthroid | Cytomel |
| Hormone supply | Converted to T3 as part of normal physiology | Supplies T3 directly |
| Usual role in primary hypothyroidism | Standard first-line replacement | Not routinely used; selected specialist discussions |
| Main comparison question | Is replacement consistent and adequate? | Is there a justified reason to change the exposure pattern? |
Treatment roles reflect NICE guidance, rather than a claim that either product is appropriate for every thyroid disorder.
What should be reviewed before adding T3?
Start with the diagnosis, how treatment is being taken and whether another problem could explain the symptoms.
NICE advises aiming for a TSH within the reference range while addressing persistent symptoms, without pushing treatment into thyroid-hormone excess. In someone still symptomatic, FT4 can add information. The guideline also warns that biotin supplements can distort thyroid blood-test results. NICE recommendations.
Consistency matters. Food, iron, calcium and other medicines can affect levothyroxine absorption; ask a pharmacist to check the exact timing for your products. A recent brand change is also worth mentioning. Follow the clinician’s or laboratory’s instructions for blood-test timing rather than assuming every thyroid test requires fasting. ATA practical guidance.
Symptoms should not be reduced to a laboratory number, but a normal result is not proof of a hidden conversion defect either. Our depression and cognitive symptoms article explores another clinical setting in which fatigue or concentration difficulties may need attention.
Is a supervised T4/T3 trial ever reasonable?
It can be discussed for selected patients, but it is not an established upgrade for everyone who remains tired.
The joint thyroid-society consensus describes unresolved questions about combination treatment and how better trials could answer them. Proposed genetic differences in conversion are an area of research, not a ready-made explanation for an individual’s symptoms. ATA consensus summary.
The ATA’s patient information discusses a time-limited combination trial as a possible approach in some people who do not feel well on T4 alone. That sits alongside NICE’s recommendation against routine use, reflecting uncertainty rather than proof that T3 never helps anyone. ATA treatment information, NICE guideline.
A useful trial needs agreed goals, monitoring and an exit plan if it does not help. The question is sustained wellbeing, not a brief burst of energy.
When should symptoms prompt a quicker review?
Palpitations, tremor or new sleep disturbance may indicate excessive hormone exposure and should be discussed promptly. Eltroxin patient leaflet.
Chest pain or a significant new heart-rhythm problem needs urgent assessment. Do not increase thyroid hormone to pursue weight loss or extra energy. If another hormone result is also abnormal, our prolactin guide explains why identifying the cause comes before adding treatment.
Do and don’t
Do: Bring symptoms, test results, supplements and your actual medicine pack to the review.
Don’t: Substitute T3 for T4 yourself, chase a suppressed TSH or assume persistent fatigue proves poor T4-to-T3 conversion.
